TFDP2 (transcription factor Dp-2) functions as a critical transcriptional coregulator that forms complexes with E2F family members to control cell cycle progression from G1 to S phase. TFDP2 binds DNA cooperatively with E2F proteins at E2 recognition sites in promoter regions of genes involved in cell cycle regulation and DNA replication 1. During terminal erythropoiesis, TFDP2 serves as an essential coregulator whose expression is induced by GATA1 and TAL1, and its knockdown results in reduced proliferation rates and altered cell cycle progression with cells accumulating in S phase 1. The protein undergoes alternative splicing regulation by Nova2 in endothelial cells, generating different isoforms with distinct subcellular localizations that integrate with PPARγ and E2F1 signaling pathways 2. TFDP2 demonstrates clinical relevance across multiple diseases: it is upregulated in HPV-positive head and neck squamous cell carcinomas 3, serves as a NetSig-predicted cancer driver candidate with tumorigenic potential comparable to known oncogenes 4, and shows significant amplification in oncogene-negative lung adenocarcinomas 4. Additionally, TFDP2 is targeted by regulatory microRNAs in various pathological contexts, including Marek's disease 5, triple-negative breast cancer 6, and obstructive sleep apnea 7, highlighting its broad involvement in disease pathogenesis.